PharmAla to supply Johns Hopkins Medicine for Clinical Trial
11 sept. 2024 08h55 HE
|
PharmAla Biotech
PharmAla completes sales agreement with Johns Hopkins Medicine, terminates contract with Red Light Holland, to present novel molecule at conference.
MAPS Awards Grant for Pilot MDMA-assisted Massed Exposure Therapy Trial
27 août 2024 07h00 HE
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
MAPS, which has incubated and funded cutting-edge psychedelic research for decades, is continuing to advance our understanding of psychedelic-assisted therapiesThis study is one of the first trials...
PharmAla Launches MDMA Clinical Trial Tool for Researchers
22 août 2024 09h07 HE
|
PharmAla Biotech
PharmAla announces the launching of a new tool for clinical researchers, and the appointment of a new CFO effective Oct. 1
MAPS Statement on FDA Complete Response Letter for MDMA-Assisted Therapy for PTSD New Drug Application
09 août 2024 21h33 HE
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
MAPS remains confident in its goal of making access to MDMA-assisted therapy for PTSD safe and legal SAN JOSE, Calif., Aug. 09, 2024 (GLOBE NEWSWIRE) -- The Multidisciplinary Association for...
PsyCan Comments on FDA Decision Re: Lykos MDMA-Assisted Therapy Application
09 août 2024 18h28 HE
|
Psychedelics Canada
Psycan comments on USFDA's recent decision to request a third phase 3 trial prior to approval of
PharmAla Comments on USFDA Decision regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002
09 août 2024 18h18 HE
|
PharmAla Biotech
PharmAla expresses disappointment in USFDA's decision to request a third Phase 3 for MDMA and announces the patent granting for a safer MDMA analog variant
PharmAla Provides Comprehensive Investor Update Following Release of Q3 Financial Statement
30 juil. 2024 08h55 HE
|
PharmAla Biotech
PharmAla releases a comprehensive investor update following its Q3 financial release, including highlights such as a 10x revenue increase and patent update
Optimi Health Secures Import Permit from Mind Medicine Australia for MDMA and Psilocybin Capsules
29 mai 2024 08h00 HE
|
Optimi Health Corp.
Optimi Health preparing to export 160 doses of MDMA and psilocybin under Australia’s Authorized Prescriber Scheme.
Optimi Health, ATMA Sign Letter of Intent To Advance Phase II Clinical Trial Group and Individual Administration Protocol For Major Depressive Disorder
22 mai 2024 08h30 HE
|
Optimi Health Corp.
Optimi Health, ATMA Sign Letter of Intent To Advance Phase II Clinical Trial Group and Individual Administration Protocol For Major Depressive Disorder
Optimi Health Provides Corporate Update
10 mai 2024 08h50 HE
|
Optimi Health Corp.
Optimi Health provides corporate update.